drugset / Trial / NCT05327790
LFMT vs Placebo in New Biologic Start for Ulcerative Colitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To compare the safety and efficacy of concomitant LFMT versus placebo in UC patients who are starting vedolizumab or ustekinumab.
Timeline
- Start
- 2022-06-03
- Primary completion
- 2027-03-31
- Completion
- 2027-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lyophilized fecal microbiota | Unknown | 5 unknown | — |